Halozyme shares jump after FDA lifts hold on trial

June 5, 2014 1:35 PM

16 0

June 5 (Reuters) - Shares of Halozyme Therapeutics Inc jumped about 11 percent a day after the U.S. Food and Drug Administration lifted a hold on a trial testing an advanced version of the company's flagship drug delivery technology.

The company said on Wednesday it would restart enrolling patients for the trial following the approval of an amended study design by an independent review boards.

Also read: FDA expands approval for Pfizer cancer drug Sutent

Read more

To category page